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HIV infection has been strongly associated with mycobacterial infections such as tuberculosis
(TB) and M. avium-intracellulare infection. In the early stages of the HIV epidemic it was
predicted that leprosy might be worsened in the presence of HIV infection. It was anticipated
that having HIV infection might be a risk factor for developing leprosy, and that more
patients would develop the anergic, lepromatous type. However, paradoxically, leprosy in
HIV infection seems to be associated with immunologically active types of disease and now
may present as an immune reconstitution syndrome. Here we review the ways in which HIV
and leprosy interact at the time of presentation and propose four different ways in which
leprosy may present in this setting.
Highly antiretroviral active therapy (HAART) is now widely used for the treatment of
HIV infection in many countries, including those endemic for leprosy. HAART suppresses
HIV multiplication and so permits both quantitative and functional reconstitution of the
immune system. However, a dysregulated recovery of pathogen-specific immune responses
may occur, especially in the first months of HAART, with the development of unusual and
strong inflammatory response against pathogens, the so-called immune reconstitution
inflammatory syndrome (IRIS).1 The most common pathogens implicated in IRIS are
M. tuberculosis, cytomegalovirus, B and C hepatitis viruses.
In 2003, the first case report of leprosy presenting as an IRIS in an HIV infected patient
newly started on HAART was published2 and subsequently other numerous case reports have
been published. Most of those cases have used the following diagnostic criteria: HIV infected
patients who developed leprosy or Type 1 leprosy reaction (T1R) within 6 months of starting
HAART, accompanied by a significant increase in CD4þ T cells. These different case
reports have highlighted different aspects of this interaction. A systematic review of these
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case reports is therefore needed so that common features of this presentation can be identified
and important aspects are illustrated.
Before these data can be presented it was necessary to review the case definitions and
discussion on the features of IRIS and particularly leprosy occurring as an IRIS since this
informs our own definition for this review. IRIS is a clinical deterioration occurring as a direct
consequence of rapid and dysregulated restoration of antigen specific immune response
during HAART,3 and diagnostic criteria should identify three aspects: clinical presentation,
immune restoration and timing of onset.
In 2004, major and minor diagnostic criteria for IRIS in AIDS were proposed.4 Major
criteria are: an atypical presentation of opportunistic infections or tumour in patients
responding to HAART, and decrease in viral load at least 1 log10 copies/ml; the minor criteria
are: an increase in CD4þ cell count after HAART, an increase in immune response specific
to a relevant pathogen and spontaneous resolution of infection without specific antimicrobial
therapy or tumour with continuation of HAART.
Some authors have suggested that, for a diagnosis of IRIS to be made, including for
leprosy as IRIS, either the clinical presentation and/or clinical course of the disease should be
atypical and be consistent with an intense inflammatory response.4 – 6 In leprosy this would
pertain in the case of a T1R. We therefore concluded that an appropriate case definition for
leprosy associated with IRIS in AIDS should include: leprosy and/or T1R and ENL
developing within 6 months of starting HAART; advanced HIV infection; low CD4þ count
before starting HAART and, CD4þ count increasing after HAART.7 Ideally, both viral load
and CD4þ cell count should be used as diagnostic criteria. If data on viral load is not
available then there should be an increase in CD4þ count associated with starting HAART.
We then used these case definitions to define all the published cases of HIV leprosy which
were then analysed and are presented here. The different clinical and laboratory aspects of the
data are presented and discussed in the context of other published data relating to both leprosy
and HIV infection. We also propose that four subgroups of leprosy IRIS can be distinguished.
Methods
DATA SOURCES AND SEARCH STRATEGY
MEDLINE and PUBMED databases were searched in January 2009 to identify all case
reports of leprosy as IRIS in HIV infected patients. The following search terms were used:
immune reconstitution phenomenon, immune reconstitution inflammatory syndrome (IRIS)
and immune reconstitution disease (IRD). Key words were leprosy, Hansen’ disease, IRIS,
immune reconstitution phenomenon, IRD, HIV and AIDS. Manuscripts in English, Spanish,
French and Portuguese were considered.
CASE DEFINITION FOR IRIS IN LEPROSY
Leprosy and/or T1R and ENL developing within 6 months of starting HAART; advanced
HIV infection; low CD4þ count before starting HAART, and CD4þ count increasing
after HAART.
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DATA SYNTHESIS
Twenty three cases were identified in 14 publications. Nineteen cases met the inclusion criteria
and were included in the analysis. Data was collected on the clinical and laboratory
manifestations, with particular focus on HIV related data such as CD4þ count and viral load.
Results
CLINICAL PRESENTATION OF LEPROSY ASSOCIATED WITH IRIS IN AIDS PATIENT
Of the 21 published cases 17 (81%) were men and four (19%) women with a mean age
36·7 years-old (range 25–54 years) (Table 1).2,8 – 18
Out of 19 IRIS cases, 13 (62%) were from Brazil, four (19%) from India, two from
French Guiana (9·5%), one from Martinique (4·75%) and one (4·75%) from Uganda.
From those 21 IRIS cases, at the moment of leprosy diagnosis 17 (89·5%) had a
histopathological diagnosis of TT or BT leprosy. Pignataro et al.8 described a patient who
was clinically diagnosed as having BL, but had a Mitsuda skin test response of 10 mm.
Talhari et al.19 describe two patients diagnosed as BL and upgraded to BT after some weeks
of continuing HAART. We therefore classified the patients as having BT type leprosy,
so giving 18 (85·7%) IRIS cases (Table 1).
Atypical leprosy lesions were reported in a few cases. Nearly all of them had evidence
of T1R. T1R plus neuritis (NT) were clearly described in eight (42%). One patient was
described presenting NT without T1R (5·2%).16 Six (28·5%) cases were reported
with ulcerated lesions and an intense inflammatory process on histological examination
(Table 1).8,9,17,19
Two leprosy patients reported as having IRIS by Martiniuk et al.20 did not meet our
diagnostic criteria for leprosy presenting as IRIS. In patient 1, the authors did not make any
comments about immune recovery (increasing T CD4þ count or decreasing viral load after
HAART) and in patient 2, the authors considered leprosy occurring as IRIS 2 years after
starting HAART (we have considered within 6 months).
EVIDENCE OF IMMUNE RESTORATION
The mean CD4þ count (pre-HAART) in these patients was 91 cells/ml (ranged 6–299
cells/ml). Twelve patients (57·2%) had CD4þ counts less than 100 cell/ml, seven (33·3%)
between 100 and 200 cell/ml, and only two (9·5%) had CD4þ counts between 201–300
cell/ml (Table 1).
Nineteen patients had a CD4þ count at the time of diagnosis of leprosy as IRIS with a
mean of 248 cells/ml (ranged 70–504 cell/ml). There was a more than two fold (2·63
increasing) in the CD4þ counts between diagnosis of leprosy and the diagnosis of IRIS, and
CD4þ count during IRIS. The increment of the CD4þ during IRIS was calculated as the
value of CD4þ count at the moment of IRIS minus the CD4þ count at baseline for each
patient, the mean of those differences was 4·34 fold (ranged from 1·5 to 12·6).
TIMING OF ONSET
The onset of IRIS in these leprosy patients had a mean and median of 8·7 weeks (range 4–24
weeks). Most of the patients (57%) developed leprosy as IRIS between 8–12 weeks (2–3
months) after initiating HAART (Table 1).
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Table 1. Clinical and laboratorial aspects of the 21 IRIS cases
CD4 £ 106/L VL copies/ml
Origin of patient/reference Clinical manifestation Age RJ/IRIS classification Sex No. weeks HAART Baseline IRIS Baseline IRIS
Uganda (2) SL/T1R 37 BT/IRIS 1 M 4 10 70 120 000 1000
Brazil (8) SL/U/T1R 48 BT/IRIS 1 M 8 147 499 – –
Brazil (8) SL/U/T1R 32 BL/IRIS 3 F 4 37 200 – –
French Guiana (9) SL/U/T1R/NT 54 BB/IRIS 1 M 6 87 257 19 000 ,650
French Guiana (9) SL/U/T1R/NT 40 TT/IRIS 4 M 8 130 278 40 701 68
Martinique (9) SL/T1R/NT 39 BT/IRIS 4 F 12 31 171 62 700 50
Brazil (10) SL/T1R 38 BT/IRIS 1 F 8–24 73 270 – –
Brazil (10) SL/T1R 25 BT/IRIS 1 M 8–24 35 100 – –
Brazil (11) SL//NT/T1R? 32 TT/IRIS 1 M 8 7 90 – –
India (14) SL/T1R/NT 28 BT/IRIS 1 M 4 125 280 150 000 1750
Brazil (12) SL/T1R 40 BT/IRIS 3 F 8? 223 436 23 000 ,50
India (13) SL/T1R/NT 32 B ?/IRIS 2 M 4 108 224 – –
Brazil (16) SL/NT 35 BT/IRIS 1 M 14 92 426 – 8300
India (15) SL/T1R/NT 35 BT/IRIS 1 M 12 299 504 – –
India (15) SL/T1R/NT 42 BT/IRIS 1 M 8 114 184 – –
Brazil (17) SL/U/T1R 28 BT/IRIS 4 M 10 33 – 6310 –
Brazil (17) SL/T1R 27 BT/IRIS 4 M 4 170 – 9230 –
Brazil (18) SL/T1R 32 BT/IRIS 1 M 8 14 172 213 000 69 000
Brazil (18) SL/T1R 53 TT/IRIS 2 M 8 104 235 – –
Brazil (19) SL/U/T1R 32 BL/BT/IRIS 1 M 4 71 257 – –
Brazil (19) SL/T1R 25 BL/BT/IRIS 4 M 24 6 77 100 000 IND
Legend: RJ – Ridley-Joplin; SL – skin lesion; U – ulceration; T1R – type 1 reaction; NT – neuritis.
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ANTIRETROVIRALS AND IRIS
Data was available on anti-retroviral treatment for 15 (71·4%) cases, in 12 (80%) AZT was
used. Some combination such as AZT þ lamivudine (3TC) was used in eight patients (53%)
and AZT þ 3TC þ abacavir was used in three (20%). However, efavirenz, nelfinavir,
didanosine, nevirapine, kaletra, indinavir also were used in combinations (Table 2). There
was no apparent relationship between the development of leprosy as IRIS and any particular
antiretroviral.
Discussion
It is a little surprising that there appears to be so few cases of leprosy presenting as IRIS. This
is in contrast to tuberculosis where there are substantial numbers of cases being reported.
However, there may be an ascertainment bias and we were only able to look at published
cases. Thus there are probably many more cases. Some will not be recognised as leprosy,
many will not be reported and only a small number will be published as case reports. It is
Table 2. Distribution of the 21 IRIS cases within leprosy IRIS classification
IRIS Classification
1 2 3 4 Total
Origin of the patient Brazil 7 1 2 3 13
French Guiana 1 0 0 1 2
India 3 1 0 0 4
Martinique 0 0 0 1 1
Uganda 1 0 0 0 1
Sex Female 1 0 2 1 4
Male 11 2 0 4 17
Ulceration No 9 2 1 2 14
Yes 3 0 1 2 6
Leprosy reaction T1R 8 1 2 3 14
T1R þ Neuritis 4 1 0 2 7
Ridley-Joplin Class TT 1 1 0 1 3
BT 9 1 1 3 14
BB 1 0 0 0 1
BL 1 0 1 1 3
CD4þ baseline 0–100 8 0 1 3 12
101–200 3 2 0 2 7
201–300 1 0 1 0 2
CD4þ IRIS* 0–100 3 0 0 1 4
101–200 2 0 1 1 4
201–300 4 2 0 1 7
. 300 3 0 1 0 4
HAART Scheme* 2 NRTI þ 1 PI 3 0 1 1 5
2 NRTI þ 1 NNRTI 4 2 1 0 7
1 NRTI þ 2 PI 1 0 0 0 1
3 NRTI 1 0 0 1 2
* There are some missing information about CD4þ IRIS and HAART Scheme.
Legend: NRTI – Nucleoside reverse transcriptase inhibitors: zidovudine (ZDV), stavudine (d4T), lamivudine
(3TC), ddI (didanosine), abacavir, tenofovir.
PI – Protease inhibitors: atazanavir, indinavir, Kaletra (lopinavir þ ritonavir), nelfinavir, saquinavir. NNRTI –
Non-nucleoside reverse transcriptase inhibitors: efavirenz, nevirapine.
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therefore important that surveillance studies should be set up to document this phenomenon.
These would probably have to be set up at regional level to ensure the adequate recruitment of
leprosy cases and then identify those who had leprosy as IRIS.
The clinical picture in this case series is of patients with highly immunologically active
leprosy who present after immune reconstitution. Nearly all the cases had the tuberculoid type
of the disease, with very active, florid skin lesions. By comparison when TB occurs as IRIS most
cases have had a typical clinical presentation.21 – 23 Most patients also had a leprosy reaction,
a further episode of immunological activity. Making comparisons about the frequency of
T1R in HIV and non HIV infected patients is difficult because T1R is the commonest
complication of borderline leprosy, occurring in at least 30% of patients in most cohort
studies, and only very small numbers of patients with leprosy as IRIS have been described.
However, an increase to 90 or 100% having reactions would be highly significant. This
again needs to be tested with larger numbers of patients. The reactions also appear to be
atypical with florid skin lesions and frequently prolonged and paradoxically needing
prolonged immunosuppression.
Probably, HIV infected patients with poor immune recovery after initiations of HAART
have subclinical leprosy and those patients with an intermediate rate of immune recovery
develop leprosy with normal presentation. Occurrence of atypical clinical presentation with
florid lesions or intense T1R and neuritis occur in those patients with a dysregulated immune
recovery.
IMMUNE MECHANISMS
The factors that determine the CD4þ T cells responses to antiretroviral treatment are only
partly known and depend on both the host and the virus. Considerable individual variation in
the reconstitution of CD4þ T cells has been noted.24 An early increase in both CD4þ and
memory CD4þ cells is noted 4 weeks after starting HAART (an increase of 1·42 times
compared to the baseline for the memory CD4 þ ) and this increase persists through
16 weeks (1·56 times) and up to 48 weeks (1·89 times). However, significant increases in
naı¨ve CD4þ lymphocytes and percentage of activated CD4þ and CD8þ T cells have
been noted within 48 weeks of starting HAART.25 This early rise (4–12 weeks) of
CD4þ lymphocytes probably results from a redistribution of CD4þ cells from lymphoid
tissue.26 This would also fit with the reported timing of presentation of leprosy lesions.
Following the stoppage of HIV replication after the initiation of HAART, a very rapid
increase in peripheral CD4þ cell that were trapped in the lymphoid tissue, is noted
particularly in the first 3–6 months. The second phase, memory CD4þ count present a
slower increase at 4–6 years, with contribution of naı¨ve CD4þ cells from thymus.24,26
Apart from those unmasking cases described originally as leprosy associated with IRIS,
when both leprosy and T1R developed after starting HAART,2,8,10,14,15 a few IRIS cases
presented with other timings. Leprosy as IRIS has also occurred as T1R in pre-existing
leprosy or skin lesions suggestive of leprosy before starting HAART.8,13,18 One case of
probable leprosy relapse after starting HAART was also published.17
Two published cases as leprosy in HIV positive patients were considered to be mimicking
IRIS because they had not started HAART at the time T1R was diagnosed.27
Immune restoration in leprosy as IRIS might be demonstrated either by an increase in
circulating CD4þ T cells (most usual) or by detecting CD4þ T cells in the skin lesions.
Demonstrating an increase in CD4þ T cells in lesions is only possible when the early lesion
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is visible and has been biopsied. Furthermore, doing counts of CD4þ cells in skin lesions has
not been standardised.
Sarno et al.28 have reported that a lower CD4þ cell count at the time of HIV diagnosis is
associated with a shorter time to developing leprosy.
LEPROSY REACTIONS
It is striking that many of these patients had clinical evidence of T1R, often with unusually
florid clinical features.
HIV infection does not appear to alter the histological appearance of leprosy lesions. These
remain typical across the spectrum with or without HIV infection. Further analysis of the
leprosy lesions at the time of IRIS is needed to establish whether is any unique features in this
setting.29,30 Typically there are low numbers of T cells (most CD8þ T cells) in lepromatous
lesions and parasitised macrophages cells; and in tuberculoid lesions, normal granuloma
formation and T cells infiltrate (most CD4þ T cells). In this timing set, HIV infection before
leprosy, cellular immune response represented by lepromin reaction, lymphoproliferation and
INF-gamma release were relatively affected in both lepromatous and tuberculoid forms.
However, during the T1R, those who had a tuberculoid type, had a positive lepromin
response.30 Associated to an unresponsiveness of BT/HIV patients to the lepromin skin test,
a failure on T cells to proliferate in response to M. leprae has been also demonstrated.31
In leprosy lesions from co-infected patients, tissue production of IFN-gamma has been
presumed since HLA-DR is expressed as are ICAM-1 and TNF-alfa.30,31 During the immune
restoration due to HAART the CD4þ and CD8þ lymphocytes expressing activation antigen
HLA-DR decrease significantly during the first 16 weeks.25 The decrease in activation marker
expression supports the hypothesis that viral replication drives immune activation.32
The Mitsuda skin reaction may change from negative to positive after starting
HAART therapy,12,18,33 however this changed from 10 mm to 7 mm in case 2 reported
in Pignataro et al.8
PROPOSAL OF A NEW CLASSIFICATION FOR LEPROSY ASSOCIATED WITH IRIS
IN AIDS
We used the current IRIS definition of leprosy as IRIS to identify two forms of leprosy as
IRIS occurring in the first few months of HAART. The first type is an inflammatory
‘unmasking’ of a previously untreated infection, in this case by M. leprae.3 The second type is
as a paradoxical clinical deterioration in pre-existing leprosy when the patients has a HAART
associated T1R. It is also possible that co-infected patients diagnosed with leprosy before
starting HAART or starting MDT could develop a leprosy reaction after HAART and this
might also be an IRIS.
Using data on timing and clinical presentation of those 21 published cases of leprosy as
IRIS we have identified four possible situations when a case of leprosy and/or T1R can be
called IRIS in AIDS patients.
Type 1. Unmasking – when patients develop leprosy or T1R after starting HAART
(Figure 1). These patients have not been diagnosed with leprosy. They are probably
incubating leprosy and the disease is only manifest after the immune restoration that occurs
caused by HAART. Of the 21 published cases, 12 (57%) were in the unmasking group
(Table 2).2,8 – 11,14 – 16,18 – 19
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IRIS type 1 
HIV+----------------------      Leprosy
T1RHAART
--------- 0 – 6 months-------------
--------- 0 – 6 months---------------------
--------- 0 – 6 months---------------------
--------- 0 – 6 months-----------
IRIS type 2
----------------HIV+/Leprosy-----------------
----------------MDT-----------------------------HAART T1R
IRIS type 3
---------------HIV+/Leprosy-----------------
HAART T1R
IRIS type 4
Skin lesions/HIV+-------  Leprosy
HAART MDT T1R
Figure key
Leprosy HIV+ T1R 
Leprosy – leprosy infection; HIV+  – HIV infection; MDT – Multi-drug therapy;
HAART – Highly Active Anti-retroviral Therapy; T1R – Type 1 Reaction; -------- -
period of time; _________ - time life. 
Figure 1. Types of IRIS occurring in leprosy and HIV co-infection.
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Type 2 – Overlap of immune restoration (paradoxical) – when leprosy has already been
diagnosed before starting HAART. When MDT and HAART are started within 3 months,
T1R occurs as a paradoxical reaction (Figure 1). Two (10·5%) of 21 leprosy as IRIS published
cases, are in this category (Table 2).13,18 T1R represents an exacerbated immune-
inflammatory response against M. leprae and is related to reactivation of the cell-mediated
immune (CMI) response.34
Type 3 – Undiagnosed leprosy or previously treated leprosy occurring at least 6 months
before HAART. When HAART is introduced, T1R occurs (Figure 1). Two (10·5%) published
cases were in this category (Table 2).8,1
Type 4 – Unmasking followed by overlap of immune restoration after HAART and
MDT. When within 6 months after start HAART, leprosy has been diagnosed and MDT
started. Later the patient develops T1R (Figure 1). From the 21 leprosy as IRIS published
cases, five (23·8%) fell into this classification (Table 2).9,17,19
Conclusions
The most common IRIS classification among the published cases was IRIS category 1 in 12
patients (57%), unmasking leprosy from a subclinical M. leprae infection.
The development of leprosy as an IRIS appears to be associated with a 1·6 increase in the
CD4þ count from the initial pre-HARRT count.
The CD4þ count can help doctors to identify leprosy as IRIS in AIDS is CD4þ count,
but clinical situations should be interpreted carefully to avoid misdiagnosis. Clinical and
immunological data are still lacking to explain the whole phenomenon.
Reactions are very common in this group of patients so the optimal way of giving
immunosuppression to already immune-suppressed patients needs to be carefully tested and
evaluated.
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